Compare iShares iBoxx $ High Yield Corporate Bond ETF (HYG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares iBoxx $ High Yield Corporate Bond ETF vs State Street SPDR S&P Biotech ETF — how do they compare? iShares iBoxx $ High Yield Corporate Bond ETF trades at $77.23 (market cap $17.89B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: iShares iBoxx $ High Yield Corporate Bond ETF is the larger of the two by market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, iShares iBoxx $ High Yield Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares iBoxx $ High Yield Corporate Bond ETF for 60 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| HYG | XBI | |
|---|---|---|
Market Cap | $17.89B | $10.11B |
Volume | 44,866,592 | 12,903,266 |
Sector | Fixed Income | Broad Market / Factor |
52-Week High | $81.28 | $169.55 |
52-Week Low | $76.90 | $104.99 |
Typical Hold Time | 60 Days | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HYG trades at $77.14, down 0.05% on the day, with technical indicators showing a bearish trend as moving averages signal strong selling pressure. The ETF maintains consistent dividend distributions with recent payouts ranging from $0.38 to $0.44. Market sentiment is heavily influenced by the broader bond selloff as Treasury yields reach multi-decade highs, creating headwinds for high-yield corporate bonds.
Current market conditions present challenges for HYG as rising interest rates pressure high-yield bond valuations. The ETF's performance remains tied to Federal Reserve policy and corporate credit conditions, with upside potential limited until bond market volatility subsides. Key risks include further rate hikes and economic slowdown impacting junk bond issuers.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
